| 刘理.益气解毒方治疗新型冠状病毒肺炎的临床研究[J].实用中西医结合临床,2023,23(1): |
| 益气解毒方治疗新型冠状病毒肺炎的临床研究 |
| Clinical Study of Yiqi Jiedu Decoction in the Treatment of COVID-19 |
| 投稿时间：2022-11-30 修订日期：2022-11-30 |
| DOI： |
| 中文关键词: 新型冠状病毒肺炎 益气解毒方 临床研究 |
| 英文关键词: COVID-19 Yiqi Jiedu Decoction Clinical research |
| 基金项目: |
|
| 摘要点击次数: 1149 |
| 全文下载次数: 630 |
| 中文摘要: |
| 目的：探讨益气解毒方治疗新型冠状病毒肺炎的临床疗效。方法：选取医院2022年1~9月收治的60例新冠肺炎患者，将随机数字表法当做基础划分小组，各30例。治疗组给予益气解毒方治疗，对照组给予西医对症治疗。观察两组新型冠状病毒核酸QRF1ab基因及N基因Ct值变化情况、住院天数及住院费用、中医证候积分、治疗总有效率及不良反应发生情况。结果：治疗后，两组新型冠状病毒核酸QRF1ab基因及N基因Ct值均显著提高，且治疗组优于对照组，组间比较存在统计学意义（P＜0.05）；治疗组与对照组相比，住院天数明显减少，住院费用明显降低，差异均有统计学意义（P＜0.05）；通过治疗后，两组证候积分低于治疗前，且治疗组更低，组间比较差异存在统计学意义（P＜0.05）；治疗有效率方面，治疗组比对照组高（P＜0.05）；不良反应方面，治疗组比对照组低（P＜0.05）。结论：益气解毒方治疗新型冠状病毒肺炎疗效明显，可以明显提升新型冠状病毒核酸QRF1ab基因及N基因Ct值，缩短治疗周期，减少住院费用，改善临床症状，不良反应发生率低。 |
| 英文摘要: |
| Objective: To explore the clinical efficacy of COVID-19. Methods: Select 60 COVID-19 patients admitted to the hospital from January to September 2022, and use the random number table method as the basic division group, with 30 cases each. The treatment group was given yiqi and detoxification prescription treatment, and the control group was given western medicine symptomatic treatment. The changes in Ct value of QRF1ab and N genes, hospitalization days, TCM syndrome points, total response rate and adverse effects of treatment reactions of the two groups were observed. Result: After the treatment, The Ct values of the QRF1ab genes and N genes were significantly improved in both groups, And the treatment group was better than the control group, Statistical significance was observed between the groups (P <0.05); In the treatment group, when compared to the control group, The number of hospital days was significantly reduced, The italization costs were significantly reduced, The differences were all significant (P <0.05); After passing through the treatment, Two groups of syndrome points were lower than before treatment, And the cultivated land in the treatment group, Statistical difference between groups (P <0.05); Treatment-efficiency aspects, The treatment group was higher than the control group (P <0.05); Adverse reactions, The treatment group was lower than the control group (P <0.05). Conclusion: The treatment of COVID-19 is obviously effective, which can significantly improve the Ct value of novel coronavirus nucleic acid QRF1ab gene and N gene, shorten the treatment cycle, reduce hospitalization costs, improve clinical symptoms, and have a low incidence of adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
